178 related articles for article (PubMed ID: 38777404)
1. SGLT2 inhibitor: 2-way superstar in nephrology?
Nangaku M
Kidney Int; 2024 Jun; 105(6):1176-1177. PubMed ID: 38777404
[No Abstract] [Full Text] [Related]
2. SGLT2 inhibitors: not every drug has the same effect.
Staruschenko A
Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1039-F1040. PubMed ID: 38695073
[No Abstract] [Full Text] [Related]
3. [SGLT2 inhibitors in diabetic and non-diabetic nephropathies].
Scheen M; Zanchi A; Martin PY; De Seigneux S
Rev Med Suisse; 2021 Feb; 17(727):378-382. PubMed ID: 33625802
[TBL] [Abstract][Full Text] [Related]
4. Are SGLT2 Inhibitors Ready for Prime Time for CKD?
Pecoits-Filho R; Perkovic V
Clin J Am Soc Nephrol; 2018 Feb; 13(2):318-320. PubMed ID: 28893920
[No Abstract] [Full Text] [Related]
5. Sweet success? SGLT2 inhibitors and diabetes.
Layton AT
Am J Physiol Renal Physiol; 2018 Jun; 314(6):F1034-F1035. PubMed ID: 29357429
[No Abstract] [Full Text] [Related]
6. More CREDENCE for SGLT2 Inhibition.
Verma S; Bhatt DL
Circulation; 2019 Oct; 140(18):1448-1450. PubMed ID: 31181959
[No Abstract] [Full Text] [Related]
7. SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now.
Taliercio JJ; Thomas G; Nakhoul GN; Vachharajani TJ; Mehdi A
Cleve Clin J Med; 2021 Jan; 88(1):59-63. PubMed ID: 33384316
[No Abstract] [Full Text] [Related]
8. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
Cruz JE; Ahuja T; Bridgeman MB
Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
Alicic RZ; Johnson EJ; Tuttle KR
Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
[TBL] [Abstract][Full Text] [Related]
10. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
Packer M
Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibitors act as metabolic transducers to restore healthy nutrient deprivation and surplus signaling in the kidney.
Kume S; Packer M
Kidney Int; 2024 Jun; 105(6):1172-1176. PubMed ID: 38777403
[No Abstract] [Full Text] [Related]
12. Adjuvant therapy in type 1 diabetes mellitus.
Cichocka E; Maj-Podsiadło A; Gumprecht J
Endokrynol Pol; 2021; 72(1):87-88. PubMed ID: 33619718
[TBL] [Abstract][Full Text] [Related]
13. Dual SGLT1 and SGLT2 inhibition: more than the sum of its parts.
Sánchez-Muñoz E; Requena-Ibáñez JA; Badimón JJ
Rev Esp Cardiol (Engl Ed); 2024 Jul; 77(7):510-514. PubMed ID: 38521442
[No Abstract] [Full Text] [Related]
14. SGLT2 inhibitors for primary prevention of cardiovascular events.
Raz I; Cernea S; Cahn A
J Diabetes; 2020 Jan; 12(1):5-7. PubMed ID: 31755238
[No Abstract] [Full Text] [Related]
15. SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.
Liu H; Sridhar VS; Perkins BA; Rosenstock J; Cherney DZI
Curr Diab Rep; 2022 Jul; 22(7):317-332. PubMed ID: 35633439
[TBL] [Abstract][Full Text] [Related]
16. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
Ninčević V; Omanović Kolarić T; Roguljić H; Kizivat T; Smolić M; Bilić Ćurčić I
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757028
[TBL] [Abstract][Full Text] [Related]
17. Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.
Hocher B; Tsuprykov O
Nat Rev Nephrol; 2017 Dec; 13(12):728-730. PubMed ID: 28989173
[No Abstract] [Full Text] [Related]
18. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
Thomas MC; Cherney DZI
Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 Inhibitors and Mechanisms of Hypertension.
Briasoulis A; Al Dhaybi O; Bakris GL
Curr Cardiol Rep; 2018 Jan; 20(1):1. PubMed ID: 29349558
[TBL] [Abstract][Full Text] [Related]
20. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
Petrykiv S; Laverman GD; de Zeeuw D; Heerspink HJL
Diabetes Obes Metab; 2018 Jan; 20(1):224-227. PubMed ID: 28685934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]